Clinical Trial Detail

NCT ID NCT03630809
Title Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1
Recruitment Recruiting
Gender
Phase Phase II
Variant Requirements Yes
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

Her2-receptor positive breast cancer

Therapies

HER2-pulsed DC1 vaccine

Age Groups:

Additional content available in CKB BOOST